key: cord-0013025-z8bcl4k2
authors: Walker, Kimberly A.; Treat, Logan P.; Sepúlveda, Victoria E.; Miller, Virginia L.
title: The Small Protein RmpD Drives Hypermucoviscosity in Klebsiella pneumoniae
date: 2020-09-22
journal: mBio
DOI: 10.1128/mbio.01750-20
sha: 0af7f259ea782ee40a12cfdacc64a3c3b89b7647
doc_id: 13025
cord_uid: z8bcl4k2

Klebsiella pneumoniae has a remarkable ability to cause a wide range of human diseases. It is divided into two broad classes: classical strains that are a notable problem in health care settings due to multidrug resistance, and hypervirulent (hv) strains that are historically drug sensitive but able to establish disease in immunocompetent hosts. Alarmingly, there has been an increased frequency of clinical isolates that have both drug resistance and hv-associated genes. One such gene, rmpA, encodes a transcriptional regulator required for maximal capsule (cps) gene expression and confers hypermucoviscosity (HMV). This link has resulted in the assumption that HMV is caused by elevated capsule production. However, we recently reported a new cps regulator, RmpC, and ΔrmpC mutants have reduced cps expression but retain HMV, suggesting that capsule production and HMV may be separable traits. Here, we report the identification of a small protein, RmpD, that is essential for HMV but does not impact capsule. RmpD is 58 residues with a putative N-terminal transmembrane domain and highly positively charged C-terminal half, and it is conserved among other hv K. pneumoniae strains. Expression of rmpD in trans complements both ΔrmpD and ΔrmpA mutants for HMV, suggesting that RmpD is the key driver of this phenotype. The rmpD gene is located between rmpA and rmpC, within an operon regulated by RmpA. These data, combined with our previous work, suggest a model in which the RmpA-associated phenotypes are largely due to RmpA activating the expression of rmpD to produce HMV and rmpC to stimulate cps expression.

moniae at the highest level of concern for antibiotic resistance threats (3, 4) . In addition, colistin-and tigecycline-resistant strains of K. pneumoniae have been isolated, severely limiting treatment options (5) . The deadly case of a pan-resistant cKp strain (resistant to 26 antibiotics) underscores the immense challenge of treating Klebsiella infections (6) .

In contrast to cKp, hypervirulent K. pneumoniae (hvKp) is community acquired by immunocompetent individuals (7) . The pathology of hvKp is more severe than that typical of cKp and can include pyogenic liver abscesses, necrotizing fasciitis, meningitis, and endophthalmitis (8, 9) . Of particular concern is the emergence of strains with both hypervirulent (hv)-associated genes or traits and the multidrug resistance that is characteristic of cKp (10) . Antibiotic resistance genes are often carried on plasmids (11, 12) , and many of the genes corresponding to hypervirulence are carried on large virulence plasmids or mobile genetic elements incorporated in the chromosome (13) (14) (15) . That these genetic entities can be horizontally transferred suggests there is an increased risk of strains acquiring both hypervirulence and multidrug resistance (16, 17) . Alarmingly, there have been recent reports of extensively resistant hypervirulent K. pneumoniae (18, 19) , and multiple strains where both hv-associated genes and antimicrobial resistance genes were present on the same mobile vector (20) (21) (22) (23) . These reports of convergence of hypervirulence and antimicrobial resistance in the same strain have heightened the need to better understand how hypervirulence genes interface with a strain's genetic background to confer hypervirulent phenotypes. This is particularly important given the extensive diversity of genetic content between K. pneumoniae strains.

Klebsiella virulence is largely attributable to lipopolysaccharide (LPS), pili, a polysaccharide capsule, and siderophores, and these are present in virtually all pathogenic strains (2) . Features specifically linked to hypervirulence include additional siderophores (2, 24) , tellurite resistance (25, 26) , and hypermucoviscosity (HMV) (2, 27, 28) . Capsule is also linked to hypervirulence, as the majority of hvKp strains have type K1 or K2 (24) , although hv-associated traits have been found in strains with other capsule types (29) . Compared to cKp, hvKp produces a thick "hypercapsule" that is thought to contribute to the HMV phenotype.

RmpA is a LuxR-like transcriptional regulator frequently encoded on virulence plasmids or on integrative chromosomal elements (ICEKp) and was initially discovered as a regulator of HMV (14, 27) . While the strong correlation between the presence of rmpA and hypervirulence has made it a key biomarker for hvKp (24, 30) , we still know very little about how rmpA contributes to HMV and hypervirulence. Previous studies established that loss of rmpA decreases capsule (cps) gene expression and reduces HMV in commonly used hvKp strains (31, 32) . We recently confirmed these rmpA-dependent phenotypes in the hvKp strain KPPR1S (28) . We also described another regulator of capsule gene expression, RmpC, which is encoded downstream of rmpA; rmpA and rmpC are cotranscribed from the same promoter that is positively regulated by RmpA (28) . Like rmpA mutants, the rmpC mutant showed reduced cps gene expression but, unlike rmpA mutants, retained HMV. We further showed that overexpression of rmpA in the wild type (WT) or the ΔrmpA and ΔrmpC mutants increased HMV. However, overexpression of rmpA did not restore cps expression in the ΔrmpC strain, and overexpression of rmpC elevated cps expression even in the ΔrmpA strain (28) . These data suggest that (i) RmpA is an important determinant for HMV but RmpC is not, (ii) reduced cps expression in the ΔrmpA strain is likely a consequence of reduced rmpC expression rather than direct regulation by RmpA, and (iii) high levels of cps expression are not necessary to confer HMV. The latter conclusion stems from the fact that the ΔrmpC mutant has reduced cps expression and capsule production (by uronic acid assay) but retains the HMV phenotype and that exogenous expression of rmpA in the ΔrmpC strain results in elevated HMV without restoring cps expression (28) . Importantly, this was the first clear evidence of a separation between capsule expression and HMV and suggests that HMV is not simply a consequence of elevated capsule production.

Here, we report the discovery of a small protein, RmpD, encoded between rmpA and rmpC that is essential for HMV. The ΔrmpD mutant is non-HMV, has no change in cps expression, and produces the same amount of uronic acid (capsule) as the wild-type parental strain. This provides corroborating evidence that HMV and capsule production result from distinct processes. Expression of rmpD is sufficient to confer HMV to a ΔrmpA mutant. It is transcribed by the promoter upstream of rmpA and therefore is also regulated by RmpA. Thus, it appears that the loss of HMV and cps expression observed in rmpA mutants is due to reduced transcription of rmpD and rmpC, respectively, and that the contribution of RmpA to these phenotypes is as an activator of this operon.

RmpD is required for hypermucoviscosity. Having observed that hypermucoviscosity (HMV) is not necessarily a consequence of elevated capsule expression from examining the individual ΔrmpA and ΔrmpC strains with complementation plasmids (28), we took one further step by similarly testing a strain that lacked the region harboring both rmpA and rmpC (strain ΔrmpAC). We predicted that introduction of pRmpA would restore HMV and that pRmpC would restore cps expression. Because the string test for HMV is qualitative, HMV was assessed by measuring the optical density at 600 nm (OD 600 ) of culture supernatants following low-speed centrifugation, an established assay for HMV (31) (32) (33) (34) ; all string test-negative strains pellet tightly, while string test-positive strains remain turbid. Expression of capsule genes was monitored using a promoter-green fluorescent protein (GFP) reporter fused to manC (manC encodes an enzyme that makes one of the K2 sugar precursors and is located in the cps locus). The manC promoter is the third of three characterized promoters in the capsule locus. The galF promoter is regulated by RmpA and RmpC in a similar manner as manC, and the wzi promoter is not regulated by these proteins (28) . While pRmpC resulted in elevated manC levels in the ΔrmpAC mutant as expected, pRmpA failed to restore HMV in this mutant ( Fig. 1A and B) . However, introduction of a plasmid containing the entire region that was deleted resulted in elevated HMV, suggesting an element contained within the intergenic space was necessary for HMV. In examining this region, the open reading frame (ORF) prediction function in Geneious R11 identified a small ORF between rmpA and rmpC (Fig. 1C) . We cloned this predicted ORF with its putative ribosome binding site (RBS) into pMWO-078, transformed it into KPPR1S, ΔrmpA, ΔrmpC, and ΔrmpAC strains, and assayed for HMV (Fig. 1D ). Introduction of this plasmid (pRmpD) resulted in a hyper-HMV phenotype in all strains, including the ΔrmpAC strain. Thus, this gene is required for HMV and was named rmpD. Transcriptional readthrough of the intergenic regions between rmpA-rmpD and rmpD-rmpC indicates rmpD is within the rmp operon ( Fig. 1C ) that is autoregulated by RmpA (28) .

To further analyze the role of rmpD, we constructed a strain lacking rmpD (ΔrmpD) and examined manC expression and HMV in this mutant. The ΔrmpD mutant had wild-type levels of manC expression and was non-HMV (Fig. 2) . The other known promoters in the capsule locus (galF and wzi) showed no expression defects in the ΔrmpD mutant (see Fig. S1 in the supplemental material). Supporting the notion that it is rmpD and not rmpA that is necessary for HMV, pRmpA was unable to restore HMV in the ΔrmpD mutant. Introduction of pRmpC into the ΔrmpD strain resulted in the same high levels of manC expression observed in other strains but did not restore HMV. Complementation of ΔrmpD with pRmpADC (formerly pRmpA-C) also resulted in an elevated level of HMV. The cultures in which rmpD is overexpressed become extremely viscous and have the consistency of a thick syrup (see Fig. S2 ) but have no change in transcription of manC (Fig. 2) . Collectively, these data suggest that rmpD is directly necessary for HMV. Given that RmpA regulates the promoter driving expression of rmpADC (28) , the well-established role of RmpA as a requisite factor for the HMV phenotype is likely due to its function as a transcriptional activator of rmpD expression.

rmpD is conserved among hvKp strains and encodes a protein. Examination of other hvKp strains used frequently for experimentation revealed that rmpD is present in these strains (see Fig. S3A ). The published sequences of two strains, KPPR1S and NTUH-K2044, have an additional ORF annotated in the rmpA-C intergenic region in the opposite orientation relative to that of rmpA. Given the operon structure, it seemed unlikely this ORF would play a role in HMV, and indeed, it does not (Fig. S3B ). To determine if these rmpD orthologs are functionally similar, we cloned the rmpD ORF and putative RBS from these strains and tested them in the WT and ΔrmpD strains of KPPR1S. Each gene retained the ability to confer hyper-HMV in both WT and ΔrmpD strains (Fig. 3A) , suggesting that the role of rmpD in HMV is conserved among various K. pneumoniae isolates.

Although there is a predicted ORF of 58 amino acids in the DNA sequence cloned in pRmpD (KPPR1S), there remained the possibility that this region encoded a regulatory RNA. To distinguish between these possibilities, we constructed a plasmid with an rmpD-2ϫFLAG fusion and were able to detect a FLAG-tagged protein close to the predicted size (Fig. 3B ), indicating that rmpD encodes a protein and not a regulatory RNA. RmpD contains a putative transmembrane domain near the N terminus, and the C terminus has numerous positively charged amino acids; these features are conserved in RmpD from other hvKp strains (Fig. 3C ). The sequence for RmpD was analyzed using Phyre2 (35) . The secondary structure is predicted to be all ␣-helical and oriented with the C-terminal region in the cytoplasm; no reliable tertiary structure was predicted.

Impact of rmpD in capsule mutants. Contributing to assumptions in the field that HMV is derived from capsule, mutants in hvKp strains that produce no or reduced levels of capsule have also typically been reported as non-HMV (31, 32, 34, 36) . To further probe the distinction between capsule production and HMV, we transformed two capsule mutants (ΔmanC and ΔwcaJ) with pRmpD to determine if these strains could become hyper-HMV. manC encodes a GDP-mannose pyrophosphorylase that produces UDP-mannose, one of the sugar precursors of K2 capsule, and wcaJ encodes the initiating glycosyltransferase (undecaprenyl phosphotransferase) involved in building the four-sugar K2 subunit. Both capsule mutants, with or without pRmpD, fully sedimented following low-speed centrifugation ( Fig. 4A ), suggesting that the HMV phenotype requires some capsule biosynthetic enzymes and may require capsule production. We therefore examined capsule production in the ΔrmpD strain using the uronic acid (UA) assay. There was no decrease in UA levels in the ΔrmpD strain compared to that in the WT, and addition of pRmpD did not lead to increased UA (Fig. 4B ). Collectively, these data imply that production of capsule is not impacted by RmpD but that at least some components of capsule must be present in order to become HMV. The negative stain, India ink, can be used to visualize capsule as zones of exclusion surrounding the bacterial cells. We stained WT, ΔrmpD, and ΔmanC strains with and without pRmpD to examine the zones in these samples; all strains also expressed gfp to verify presence of the bacteria. WT bacteria showed exclusion zones that varied somewhat in size, whereas the rmpD-deficient bacteria had thinner uniform exclusion zones (Fig. 5) . When rmpD was overexpressed in either strain, the bacteria had uniformly large exclusion zones. As predicted, no exclusion zones were observed from staining of ΔmanC bacteria, although the field had ample bacteria present. Given that there was no difference in the amount of UA between the WT and ΔrmpD strains, these data suggest that the material forming the abundant exclusion zones is different from a typical UA-containing capsule and that the HMV material also excludes the stain. There are several known regulators of capsule gene expression, of which, our lab has identified three and studied five (28, 36) . These mutants (ΔrmpA, ΔrmpC, ΔkvrA, ΔkvrB, and ΔrcsB) all have reduced UA levels and capsule expression, and all but ΔrmpC are from several hvKp strains were identified using Geneious Prime, cloned, and expressed in either WT or ΔrmpD strains, which were assayed for mucoviscosity. One-way ANOVA with Tukey's posttest was used to determine significance using the WT or the ΔrmpD mutant with vector as the reference. ****, P Ͻ 0.0001. (B) Western blot analysis of whole-cell extracts from WT carrying pRmpD-2ϫFLAG probed with ␣-FLAG antibody. (C) RmpD from known hvKp strains. c, chromosomal copy; p, plasmid copy; orange and blue boxes, residues conserved in chromosomal and plasmid copies, respectively; gray boxes, nonconserved residues; *, fully conserved residues; red residues, positively charged side chains, Black lines indicate predicted transmembrane domain regions: residues 3 to 23 predicted by Geneious Prime and 13 to 28 predicted by Phyre2. Accession numbers for these sequences are in the Text S1 in the supplemental material. One-way ANOVA with Tukey's posttest was used to determine significance to obtain all pairwise comparisons. ns, not significant; ****, P Ͻ 0.0001. production in these mutants (Fig. 6B) , further indicating that strains with low capsule expression and UA production are still capable of becoming HMV.

KPPR1S produces the enterobacterial common antigen (ECA) and LPS. A recent report showed that mutants in LPS and ECA pathways had reduced HMV (determined by sedimentation) (34, 37) . To more clearly ascertain if either of these exopolysaccharides contributed to HMV, we tested a strain with a disruption in wecA, which encodes an undecaprenyl phosphotransferase; this mutant produces normal levels of UA but lacks both LPS and ECA and is attenuated in the pneumonia model (38) . The wecA mutant showed WT-like HMV and became hyper-HMV when rmpD was overexpressed (see Fig. S5 ). Thus, LPS and ECA are not likely to be directly required for HMV. However, this does not rule out the possibility that other mutations in these pathways could have pleiotropic effects leading to reduced HMV. Additionally, it is possible that some enzymes required for LPS or ECA could contribute to HMV independently of their role in LPS or ECA. rmpD contributes to immune evasion and virulence. One of the virulence phenotypes associated with capsule is the blocking of adherence and phagocytosis (39) . To determine if HMV specifically contributed to these processes, we performed adherence and internalization assays with the macrophage-like J774A.1 cell line. The WT strain showed approximately 5% adherence, and the ΔmanC mutant showed nearly 70% adherence (Fig. 7A) . The ΔrmpD strain behaved like the acapsular manC mutant, with ϳ85% adherence. The WT or ΔrmpD strains with pRmpD were virtually nonadherent, with less than 1% of the bacteria attached. This reduction was not observed in the ΔmanC mutant with pRmpD, most likely because it remains non-HMV. Because the ΔrmpD strain still produced capsule at the WT level and the attachment phenotype was the same as a capsule mutant, it appears that the HMV phenotype, rather than capsule per se, is the main factor blocking attachment to host cells. A similar trend was observed for internalization of these strains (Fig. 7B) . Less than 1% of WT cells were intracellular, and approximately 35% of the ΔmanC bacteria (with and without pRmpD) were intracellular. No bacteria were recovered from WT or ΔrmpD with pRmpD. Only ap- proximately 6% of the ΔrmpD bacteria were internalized; this is significantly more than WT but also significantly less than the ΔmanC mutant. These results suggest that (i) HMV blocks both adherence and internalization and (ii) capsule-positive strains are still somewhat protected against phagocytosis, even if non-HMV. Collectively, HMV appears to provide the primary barrier to adherence, while capsule and HMV each contribute to prevention of phagocytosis by macrophages. Based on the results of the in vitro virulence-associated assays, we next tested the ΔrmpD mutant in our mouse pneumonia model and found it to be essential for virulence in vivo. At 24 h postinoculation (hpi), the ΔrmpD mutant was recovered from the lungs at levels approximately 4 logs lower than that of the WT and was essentially cleared by 72 hpi (Fig. 7C) . In the spleens, the ΔrmpD mutant was recovered at lower numbers than the WT at 24 hpi, but WT levels were often low at this time point (Fig. 7D) . However, by 72 hpi, the WT colonized the spleens to ϳ10 8 CFU/g and the rmpD mutant was not recovered. A strain with the rmpD gene restored at the native site (rmpD comp ) behaved like the WT, indicating that the defects observed from ΔrmpD were indeed due to loss of rmpD.

Hypermucoviscosity (HMV) is a phenotype possessed by a subset of K. pneumoniae strains and is one of the phenotypes associated with hypervirulent strains (2) . RmpA has been established as an essential factor for HMV, and rmpA mutants also show reduced capsule gene expression (28, 31, 32) . Thus, it has long been assumed that the HMV phenotype was a consequence of abundant capsule production in excess of that observed in classical strains. This arose despite statements in some early studies that HMV did not appear to be linked to capsule production (27, 40) . However, fluorescein isothiocyanate (FITC) staining of an hv K. pneumoniae strain incubated with K2 antisera suggested the extracapsular substance associated with HMV contained capsular material (41) . Although it has been 30 years since the discovery of RmpA, no direct regulation by RmpA of cps expression (or that of other genes) has been demonstrated. In our investigations into the contributions of RmpA to hypervirulence, we confirmed its role in HMV and cps expression but also ascertained that the mechanisms contributing to these phenotypes are much more complex than had been presumed (28) . We identified a downstream gene encoding RmpC, a putative transcriptional regulator that modulates cps expression, and found that rmpA and rmpC are in an operon that is autoregulated by RmpA. RmpA and RmpC have distinct functions in that the ΔrmpA mutant is non-HMV but the ΔrmpC mutant retains HMV. Both mutants have similar reductions in cps expression; however, overexpression of rmpC complements cps expression even in strains lacking rmpA. While RmpC has also not been demonstrated to directly regulate cps promoters, these data indicated that RmpA was not likely to be a direct regulator of the cps gene. We thus concluded that RmpA controlled HMV while RmpC controlled cps expression in work that provided the first clear evidence separating the phenotypes of HMV and capsule levels.

In evaluating cps expression and HMV in what we thought was a double ΔrmpA-rmpC mutant, it became clear that the story was not as simple as suggested by the analysis of individual rmpA and rmpC mutants. Namely, pRmpA did not restore HMV to this ΔrmpADC mutant, but a plasmid containing the entire deleted region (pRmpADC) did restore HMV. In the present study, we report the initial characterization of RmpD, a small protein encoded in the region between rmpA and rmpC and within the rmp operon. The data presented here suggest that RmpD is the key factor driving the HMV phenotype. Collectively, our data support a model in which the role played by RmpA in the HMV and cps expression phenotypes is to activate expression of rmpD and rmpC. This is evidenced by (i) the restoration of HMV in the ΔrmpA and ΔrmpADC strains with pRmpD, and restoration of cps expression in the ΔrmpA and ΔrmpADC strains with pRmpC, and (ii) the inability of pRmpA to restore HMV in the ΔrmpD strain or cps expression in the ΔrmpC strain. Given that several RmpD orthologs were able to complement HMV in the ΔrmpD strain and that rmpD is present in strains that also have rmpA and rmpC, we speculate that RmpD is part of a conserved mechanism conferring HMV to K. pneumoniae. Little information can be gleaned about how RmpD acts from sequence and structural analyses. It is predicted to be ␣-helical and anchored in the inner membrane by an N-terminal transmembrane domain with the C terminus positioned in the cytoplasm. As the C-terminal region of all RmpD orthologs contains a number of positively charged residues, we speculate that these charges allow for specific protein-protein interactions that mediate the HMV phenotype.

Several lines of evidence further support the notion that production of capsule and HMV are separable. First, deletion of rmpD did not alter UA levels, suggesting that production of the capsular material is unaffected by this mutation. Second, strains that are hyper-HMV from overproduction of RmpD did not produce more UA than the WT strain. Third, trans expression of rmpD was able to restore HMV in the regulatory mutants (ΔrmpA, ΔkvrA, ΔkvrB, and ΔrcsB), that all have reduced cps expression and capsule production and are non-HMV. Each of these regulators activate transcription of the rmpADC promoter (28); thus, the loss of HMV in these mutants is most likely due to reduced expression of rmpD. Curiously, even though we can detect almost no expression from the manC promoter in the ΔrcsB strain (28) , introduction of pRmpD in the ΔrcsB mutant, but not in the ΔmanC mutant, results in hyper-HMV. Either very low levels of mannose-1-phosphate guanylyltransferase are sufficient for HMV production or HMV does not actually require this enzyme and the HMV defect in a ΔmanC strain is an indirect effect of loss of this gene. Lastly, a recent study has identified several K. pneumoniae transposon mutants with normal capsule production and reduced HMV (42) .

In mucoviscosity and adherence assays, the ΔrmpD strain behaves nearly identically to the capsule mutant ΔmanC. Both mutants pellet tightly and are highly adherent to host cells. The hyper-HMV strains (WT and ΔrmpD with pRmpD) are essentially nonadherent, but the non-HMV ΔmanC plus pRmpD strain remains highly adherent. This raises the question as to whether the antiadherence property of hvKp is dependent on capsule or on HMV. Given that the ΔrmpD strain is encapsulated, it appears that HMV is a more critical determinant for blocking adherence. This is consistent with the non-HMV ΔrmpA strain having a more severe virulence defect than the HMV-positive ΔrmpC strain in the mouse pneumonia model (28) . Enumeration of bacteria internalized by J774A.1 cells showed a similar trend to adherence, except that the ΔrmpD strain was internalized less efficiently than the ΔmanC strain. These data appear to suggest that HMV is a stronger deterrent to adherence than capsule, but that both capsule and HMV provide protection against phagocytosis in an additive manner. As this is the first attempt to examine strains with defects in HMV but not capsule production, similar analyses will need to be performed in other hvKp strains to determine if these trends are generally applicable or unique to KPPR1S. In the in vivo pneumonia model, the ΔrmpD mutant is severely attenuated, with a defect similar to that of the ΔrmpA mutant (28) . This reinforces that HMV is an essential virulence factor in immunocompetent mice and suggests that capsule, while certainly providing some protection against host defenses, is insufficient in the absence of HMV for establishment of a lethal infection in mice. These data illustrate how HMV distinctly contributes to the hypervirulence of K. pneumoniae isolates. Support for this comes from reexamination of the virulence defects of the ΔrmpA and ΔrmpC strains. While it is possible that RmpA regulates additional virulence factors, the loss of rmpD expression in the ΔrmpA mutant likely contributes to the stronger virulence defect in the ΔrmpA mutant than in the ΔrmpC mutant. Similarly, analysis of KPPR1 genes essential for infection in a mouse pneumonia model identified mutations in VK055_5096 as deficient for virulence (33) . This orf is located immediately upstream of rmpA (VK055_5097), and the transposon insertion quite likely impaired expression of the rmp locus. Furthermore, the virulence plasmidborne rmp locus was found to be associated with liver abscess formation by NTUH-K2044 (43) .

Complicating the notion that HMV is not simply a consequence of overabundant capsule production is that hyper-HMV did not occur in capsule-deficient mutants carrying pRmpD. This suggests that strains can be capsule positive/HMV positive or capsule positive/HMV negative but not capsule negative/HMV positive. One possible explanation for this is that the HMV material is capsular but that the export is altered in the presence of RmpD. This situation would mean that even reduced levels of biosynthetic enzymes such as those found in the regulatory mutants are sufficient to yield the extra polysaccharides. A second explanation is that HMV is a polysaccharide distinct from capsule, but that some cps-encoded functions are required to produce this material. A third possibility is that the HMV material is a modified form of capsule, and the presence of RmpD influences synthesis or export of the altered polysaccharide. That capsule-like material is part of HMV material is supported by the K2-positive staining of the HMV substance from a WT strain but not from non-HMV mutants (41) .

To date, HMV has primarily been associated with hv K1 and K2 strains, but more than 130 capsule types of K. pneumoniae have been identified (44) . Of significant concern is the number of recent reports of strains with both multidrug resistance and hvassociated genes, including rmpA (and quite likely rmpD and rmpC) (18) (19) (20) (21) (22) (23) . These strains are genetically quite distinct (including capsule type) from the hvKp that have been circulating, and it is not known to what degree acquisition of the rmpADC locus will impact HMV and virulence of these strains. While we have shown that RmpD from either a K2 or K1 strain can confer HMV in a K2 strain, it is not clear if there is capsule type specificity for this RmpD function. We also do not know, beyond a few cps genes, what, if any, other genes are necessary to confer HMV or if these genes are conserved in all K. pneumoniae strains. A better understanding of what is required for HMV and how genetic background influences the HMV-associated hypervirulent phenotypes will be important for determining the risks associated with carbapenem-resistant (CR) cKp strains that acquire rmpADC.

Additional experimental detail is available in Text S1 in the supplemental material. Bacterial strains, plasmids and growth conditions. The strains and plasmids used in this work are listed in Table 1 . Escherichia coli strains were grown in LB medium at 37°C. K. pneumoniae was grown at 37°C in M9 medium supplemented with 0.4% glucose and 0.2% Casamino Acids (M9-CAA). Unless otherwise noted, saturated overnight cultures were diluted to an OD 600 of 0.2 and grown for 6 h. Antibiotics were used where appropriate: kanamycin (Kan), 50 g/ml; rifampin (Rif), 30 g/ml; spectinomycin (Sp), 50 g/ml. For expression of genes cloned into pMWO-078, 100 ng/ml anhydrous tetracycline (aTc) was added to the medium at the time of subculture. The primers used for cloning are listed in Table S1 . In-frame gene deletions in K. pneumoniae were constructed by allelic exchange using pKAS46based plasmids as described previously (28) . Complementation plasmids were constructed using pMWO-078 (45) . Plasmids containing promoter-gfp fusions were cloned in pPROBE-tagless (46) . The gfp reporter and complementation plasmids were introduced into K. pneumoniae by electroporation as described previously (28) .

Transcriptional gfp reporter assays. Relative fluorescent units (RFU) and OD 600 were measured from bacterial cultures diluted 1:10 by using a Synergy H1 plate reader (Bio-Tek, Winooski, WI) and a Bio-Rad spectrophotometer (Bio-Rad, Hercules, CA), respectively. Data are presented as RFU/OD 600 , normalized to the activity from the wild-type strain in each assay.

Assessment of capsule production and HMV. Uronic acid was measured essentially as described previously (38) . Mucoviscosity of liquid cultures was determined by measuring the OD 600 of the culture supernatant following low-speed centrifugation as described previously (28) . Centrifugation was chosen over the string test because it is semiquantitative, whereas the string test is purely qualitative. All strains that pellet tightly are string test negative, while those with turbid supernatants are string test positive.

Immunoblotting. Whole-cell lysates from cultures grown in M9-CAA with aTc for 6 h were separated on 15% SDS-PAGE gels, transferred to polyvinylidene difluoride (PVDF) membranes, probed with ␣-FLAG antibody (Sigma, M2 monoclonal antibody), and detected with chemiluminescence.

Adherence and internalization assays. Adherence assays were performed essentially as described previously (36) using J774A.1 cells. For adherence, the cells were pretreated with cytochalasin D 1 h prior to inoculation to prevent internalization of the bacteria. For internalization, cytochalasin D was omitted, and the wells were treated with 200 g/ml gentamicin after a 1-h coincubation. Recovered bacteria (as CFU) are reported as a percentage of the inoculum CFU.

Murine pneumonia model. All animal studies were approved by the Institutional Care and Use of Committee of UNC-CH. Anesthetized C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were inoculated with 2 ϫ 10 4 CFU intranasally as described previously (36) . Mice were sacrificed at 24 h and 72 h postinoculation; lungs and spleens removed for determination of bacterial enumeration. The data are presented as CFU/gram tissue.

India ink staining. Bacterial cultures carrying a constitutively expressing gfp reporter (pJH026) were grown as for all other assays. Equal volumes of culture and India ink were mixed on a glass slide and overlaid with a coverslip. Microscopy was performed using a Keyence BZ-X810 microscope at ϫ1,000 magnification.

Statistics and replicates. Statistical tests for each experiment are given in the figure legends and were performed using GraphPad Prism 8.2. For every assay, a minimum of three assays were performed, each with biological replicates. Typically, a representative experiment is presented. In all bar graphs, bars are average values and error bars indicate standard deviations (n Ն 3).

Supplemental material is available online only. TEXT S1, DOCX file, 0.1 MB. 

We thank Lauren Mobley for assistance with the assays shown in Fig. S5 . We thank Rita Tamayo for thoughtful discussions on the manuscript and for use of the Keyence BZ-X810 microscope.

This work was supported by R21AI132925 to V.L.M. from NIAID. 

Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors

Klebsiella pneumoniae: going on the offense with a strong defense

Antibiotic resistance threats in the United States

Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics

Treatment options for colistin resistant Klebsiella pneumoniae: present and future

Genomic analysis of a pan-resistant isolate of Klebsiella pneumoniae

Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed

Hypervirulent Klebsiella pneumoniae

Hypervirulent Klebsiella pneumoniae -clinical and molecular perspectives

Convergence of carbapenem-resistance and hypervirulence in Klebsiella pneumoniae

Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding

The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrugresistant Enterobacteriaceae

Sequencing and analysis of the large virulence plasmid pLVPK of Klebsiella pneumoniae CG43

Characterization of integrative and conjugative element ICEKp1-associated genomic heterogeneity in a Klebsiella pneumoniae strain isolated from a primary liver abscess

Genetic diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICEKp in Klebsiella pneumoniae populations

A conjugative plasmid that augments virulence in Klebsiella pneumoniae

Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of Klebsiella pneumoniae

A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study

An outbreak of carbapenem-resistant and hypervirulent Klebsiella pneumoniae in an intensive care unit of a major teaching hospital in Wenzhou

Carriage of bla KPC-2 by a virulence plasmid in hypervirulent Klebsiella pneumoniae

Virulence genes in isolates of Klebsiella pneumoniae from the UK during 2016, including among carbapenemase genepositive hypervirulent K1-ST23 and "non-hypervirulent" types ST147, ST15 and ST383

Hybrid resistance and virulence plasmids in "high-risk" clones of Klebsiella pneumoniae, including those carrying bla NDM-5

Convergence of virulence and MDR in a single plasmid vector in MDR Klebsiella pneumoniae ST15

Identification of biomarkers for differentiation of hypervirulent Klebsiella pneumoniae from classical K. pneumoniae

Identification of pathogenicity-associated loci in Klebsiella pneumoniae from hospitalized patients

Association of tellurite resistance with hypervirulent clonal groups of Klebsiella pneumoniae

Mucoid phenotype of Klebsiella pneumoniae is a plasmid-encoded virulence factor

A Klebsiella pneumoniae regulatory mutant has reduced capsule expression but retains hypermucoviscosity

Differential host susceptibility and bacterial virulence factors driving Klebsiella liver abscess in an ethnically diverse population

Multiplex PCR analysis for rapid detection of Klebsiella pneumoniae carbapenem-resistant (sequence type 258 [ST258] and ST11) and hypervirulent (ST23, ST65, ST86, and ST375) strains

RmpA regulation of capsular polysaccharide biosynthesis in Klebsiella pneumoniae CG43

The role of Klebsiella pneumoniae rmpA in capsular polysaccharide synthesis and virulence revisited

Genome-wide identification of Klebsiella pneumoniae fitness genes during lung infection

The capsule regulatory network of Klebsiella pneumoniae defined by density-TraDISort

The Phyre2 web portal for protein modeling, prediction and analysis

Identification of two regulators of virulence that are conserved in Klebsiella pneumoniae classical and hypervirulent strains

Transposon mutagenesis screen of Klebsiella pneumoniae identifies multiple genes important for resisting antimicrobial activities of neutrophils in mice

Identification of Klebsiella pneumoniae virulence determinants using an intranasal infection model

The role of the O and K antigens in determining the resistance of Klebsiella aerogenes to serum killing and phagocytosis

Positive control of colanic acid synthesis in Escherichia coli by rmpA and rmpB, two virulence-plasmid genes of Klebsiella pneumoniae

Enhancement of extracapsular polysaccharide synthesis in Klebsiella pneumoniae by RmpA2, which shows homology to NtrC and FixJ

A systematic analysis of hypermucoviscosity and capsule reveals distinct and overlapping genes that impact Klebsiella pneumoniae fitness

Clinical and genomic analysis of liver abscess-causing Klebsiella pneumoniae identifies new liver abscess-associated virulence genes

Identification of Klebsiella capsule synthesis loci from whole genome data. Microb Genom 2:e000102

Low copy expression vectors for use in Yersinia sp. and related organisms

Improved gfp and inaZ broadhost-range promoter-probe vectors

A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR

A serendipitous mutation reveals the severe virulence defect of a Klebsiella pneumoniae fepB mutant

Positive selection vectors for allelic exchange

A phenotype at last: essential role for the Yersinia enterocolitica Ysa type III secretion system in a Drosophila melanogaster S2 cell model

K.A.W., V.L.M., and L.P.T. designed research; L.P.T., K.A.W., and V.E.S. performed experiments; K.A.W., L.P.T., and V.L.M. analyzed data and wrote the paper.